Bokvist K, et al. - Researchers assessed if long-term glycemic changes result from a 4-week course of 14 mg weekly glucagon-like peptide-1 (GLP-1) agonist LY2428757 combined with 3 mg or 2 mg daily gastrin analogue TT223 (LY+TT223). In 151 patients with adequately controlled type 2 diabetes mellitus ±metformin, LY+TT223 (3 mg), LY+TT223 (2 mg), LY+TT223 placebo (LY-only) or LY placebo +TT223 placebo (placebo) were randomly given as a 4-week course. During the active treatment phase, LY groups showed reductions in HbA1c. The combination of TT223 with LY during treatment or follow-up did not result in additional glycemic effects. Overall, the investigators concluded that combination therapy with GLP-1+gastrin did not improve glycemic control over GLP-1 alone. Nausea and vomiting were more frequent with LY+TT223 compared to LY-only.